4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q3 EPS of ($0.24), $0.37 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $20.2 million versus the consensus estimate of $9.18 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.